Zimbabwe has turned down a major US healthcare agreement valued at $367m (£272m) over five years due to the United States' demand for sensitive information.
This rejection became public after a government memo from December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the agreement was "skewed".
An official representative later clarified that the US was requesting health data for research and commercial gain but refused to guarantee the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable process of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had furnished more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged more dialogue to find a deal agreeable to all parties so the country's critical HIV treatment initiative can be sustained.
Wider Implications
This rejection follows a comparable case in Kenya, where a court halted a related health funding agreement following concerns were filed about the safety of Kenyans' health data.
Since resuming office last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump stated its spending was "inefficient" and his government was pursuing government-to-government deals to boost openness and accountability.
According to statements, 16 African countries have so far agreed to these new agreements, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving antiretroviral therapy through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to surrender its biological resources and data over an extended period, with no corresponding guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that shared data," Mangwana explained.
"Effectively, our nation would provide the basic resources for scientific discovery without any assurance that the resulting innovations would be available to our people should a future pandemic arise."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its pursuit of bilateral health agreements were disrupting frameworks previously set up through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing framework created to deal with potential pandemics.
"This system is intended to guarantee that when a nation provides its information, the benefits – such as medicines and cures – are shared equitably, not monopolised solely by those with the funds to develop them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how future co-operation might be structured in a manner that honours the independence and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the government's concerns, but urged that talks must proceed considering much of the nation's HIV programmes relied on international support.
"Where technical issues arise, including those relating to data governance or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," the group added.
The halted deal underscores the continuing tensions between accepting vital foreign assistance and safeguarding national sovereignty in an ever more data-driven world.